IRMD vs SEPN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IRMD presents a dichotomy between exceptional operational performance and extreme valuation premiums. While the Piotroski F-Score of 4/9 indicates stable financial health and the company boasts an impressive 76.75% gross margin and a consistent 25-quarter earnings beat record, the stock is trading significantly above its Graham Number ($17.07) and Intrinsic Value ($51.62). The strong fundamental growth is currently offset by bearish insider activity from the CEO and a completely bearish technical trend (0/100).
Septerna exhibits a stark disconnect between fundamental financial health and market sentiment. The Piotroski F-Score of 2/9 indicates weak financial health, characterized by negative profitability and consistent earnings misses (0/4 beats in the last year). However, the company maintains a strong liquidity position with a Current Ratio of 4.73 and very low debt (D/E 0.06), which is typical for a clinical-stage biotech. While analysts maintain a 'strong_buy' rating with a target of $44.43, the combination of bearish insider selling and a high Price/Sales ratio (25.54) suggests a highly speculative valuation based on future pipeline success rather than current performance.
Compare Another Pair
Related Comparisons
IRMD vs SEPN: Head-to-Head Comparison
This page compares IRADIMED CORPORATION (IRMD) and Septerna, Inc. (SEPN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.